Renaissance Capital logo

Odyssey Therapeutics Filed, US Offering, Nasdaq: ODTX

Phase 2-ready biotech developing precision therapies for autoimmune diseases.

Industry: Health Care

Odyssey is a clinical-stage biopharmaceutical company led by a team and board of drug hunters seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. To accomplish this, we are developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. We believe our deep understanding of immunobiology, coupled with leading expertise in medicinal, computational and protein chemistry, structural biology, genetics and pharmacology allows us to identify and drug key signaling nodes that drive disease. We have prioritized targets where we believe the underlying disease biology is understood through genetic, clinical or translational evidence. Our most advanced programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, for which we intend to commence a Phase 2a monotherapy trial for ulcerative colitis, or UC, in the first quarter of 2025 and a Phase 2a combination trial with vedolizumab in the first half of 2026, and two preclinical programs: a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains (which we term a V-body).
IPO Data
IPO File Date 01/17/2025
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
Jefferies
more
Company Data
Headquarters Boston, MA, United States
Founded 2021
Employees at IPO 151
Website odysseytx.com

Odyssey Therapeutics (ODTX) Performance

Created with Highcharts 10.3.2Chart context menuODTX vs. IPO Index (IPOUSA)25. Nov2. Dec9. Dec16. Dec23. Dec30. Dec6. Jan13. Jan20. Jan27. Jan3. Feb10. Feb17. Feb0%-10%-5%+ 5%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index